These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 20838741)

  • 1. Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
    Amin AN; Girard F; Samama MM
    Thromb Haemost; 2010 Nov; 104(5):955-61. PubMed ID: 20838741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.
    Bergmann JF; Cohen AT; Tapson VF; Goldhaber SZ; Kakkar AK; Deslandes B; Huang W; Anderson FA;
    Thromb Haemost; 2010 Apr; 103(4):736-48. PubMed ID: 20135072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
    Yusen RD; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Chen M; Deslandes B; Turpie AG
    Thromb Haemost; 2013 Dec; 110(6):1152-63. PubMed ID: 24085227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin.
    Verhamme P; Motte S; Claes N; Verhaeghe R; Hermans C
    Int Angiol; 2010 Feb; 29(1):58-63. PubMed ID: 20224534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
    Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Huang J; Cao Y; Liao C; Wu L; Gao F
    Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
    Wiseman DN; Harrison J
    N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic outcomes with appropriate or partial prophylaxis.
    Amin AN; Lin J; Johnson BH; Schulman KL
    Thromb Res; 2010 Jun; 125(6):513-7. PubMed ID: 19931121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.
    Dranitsaris G; Jelincic V; Choe Y
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):233-42. PubMed ID: 22387576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
    N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism following primary total hip arthroplasty.
    Hitos K; Fletcher JP
    Int Angiol; 2009 Jun; 28(3):215-21. PubMed ID: 19506541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.